Sydvestjysk sygehus - Esbjerg

The trials here

What the 6 trials at this site are about, from their registry records.

Conditions

• Multiple myeloma2 trials
• Acute myeloid leukaemia1 trial
• Asthma1 trial
• Chronic lymphocytic leukaemia1 trial
• Myelodysplastic syndromes1 trial
• Osteoporosis1 trial
• Ulcerative colitis1 trial

Phase

• Phase 33 trials
• Phase 21 trial
• Phase 41 trial

Status

• Completed3 trials
• Active, not recruiting2 trials
• Recruiting1 trial

Lead sponsor

• Christoffer Johansen1 trial
• Copenhagen University Hospital, Rigshospitalet1 trial
• Eli Lilly and Company1 trial
• Enzene Biosciences Ltd.1 trial
• German CLL Study Group1 trial
• and 1 more

Running trials

• Active, not recruiting

  A Real-world, Head-to-head Comparison of Dupilumab Versus Mepolizumab in Danish Patients With Chronic Rhinosinusitis With Nasal Polyps

  NCT05942222· Phase 4· Copenhagen University Hospital, Rigshospitalet· Source

• Recruiting

  Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)

  NCT05444348· Christoffer Johansen· Source

  Contact: Cæcilie Borregaard Myrhøj

• Active, not recruiting

  Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

  NCT04717700· Phase 2· Ida Bruun Kristensen· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Acute myeloid leukaemia1 recruiting
• Multiple myeloma1 recruiting
• Myelodysplastic syndromes1 recruiting

Closed trials

• Completed

  A Phase 3 Study to Compare Biosimilar Denosumab With Prolia®

  NCT05405725· Phase 3· Enzene Biosciences Ltd.· Source

• Completed

  An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)

  NCT03518086· Phase 3· Eli Lilly and Company· Source

• Completed

  Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

  NCT02950051· Phase 3· German CLL Study Group· Source